Protective effects of salvianolate on microvascular flow in a porcine model of myocardial ischaemia and reperfusion  by Han, Beibei et al.
Archives of Cardiovascular Disease (2011) 104, 313—324
CLINICAL RESEARCH
Protective effects of salvianolate on microvascular
ﬂow in a porcine model of myocardial ischaemia and
reperfusion
Effet protecteur du salvianolate sur la microcirculation dans un modèle
d’ischémie myocardique reperfusion chez le porc
Beibei Hana, Xin Zhangb, Qingyong Zhanga,
Gang Zhaoa, Junbo Weia, Shixin Maa,
Wei Zhua, Meng Weia,∗
a Division of Cardiology, Shanghai Sixth People’s Hospital, Shanghai Jiao Tong University
School of Medicine, Shanghai, China
b Division of Cardiology, The First Afﬁliated Hospital of Baotou Medical College, Inner
Mongolia Province, China
Received 13 April 2010; received in revised form 14 February 2011; accepted 22 February 2011
Available online 8 June 2011
KEYWORDS
Salvianolate;
Ischaemia/reperfusion,
injury;
Microvascular ﬂow;
Oxidative stress;
Apoptosis
Summary
Background.— Microvascular reﬂow is crucial for myocyte survival during ischaemia/
reperfusion injury.
Aims.— We aimed to assess if salvianolate, a highly puriﬁed aqueous extract from Radix salviae
miltiorrhizae, could improve impaired microvascular reﬂow induced by ischaemia/reperfusion
injury, using a porcine closed-chest model.
Methods.— Left anterior descending coronary artery ligation was created by balloon occlusion
for 2 h followed by reperfusion for 14 days. Salvianolate was administrated intravenously for
7 days at low dose (5mg/kg/day), high dose (10mg/kg/day) or high dose combined with one
20mg intracoronary bolus injection just at the beginning of reperfusion. Control-group animals
were only given the same volume of saline.
Results.— After 14 days of reperfusion, animals treated with high-dose salvianolate showed
improved myocardial perfusion assessed by real-time myocardial contrast echocardiography
and coloured microspheres. The beneﬁcial effect was further supported by increased capillary
density and decreased infarct size. All these effects eventually resulted in well-preserved car-
diac function detected by echocardiography. Moreover, we also demonstrated that salvianolate
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administration was associated with elevated superoxide dismutase activity, thioredoxin activ-
ity and glutathione concentration, and reduced malondialdehyde concentration, which,
in turn, resulted in a signiﬁcant decrease in terminal deoxynucleotide transferase-
mediated dUTP nick end labelling-positive cells and an increased ratio of Bcl-2 to Bax
expression.
Conclusion.— Intravenous salvianolate at a dose of 10mg/kg/day for 7 days had signiﬁcant
beneﬁcial effects on myocardial microvascular reﬂow, which were associated with decreased
oxidative stress and apoptosis.
© 2011 Elsevier Masson SAS. All rights reserved.
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Résumé
Justiﬁcation.— Le ﬂux dans la microcirculation est déterminant pour la survie myocytaire
pendant les lésions d’ischémie/reperfusion.
Buts.— Nous avons pour objectifs d’évaluer si le salvianolate, un extrait hautement puriﬁé
provenant demiltiorrhizae salviae radix pouvait améliorer le ﬂux dans la microcirculation,
altéré par les lésions d’ischémie/reperfusion dans un modèle de porcs à thorax fermés.
Méthode.— La ligature de l’artère interventriculaire antérieure a été créée par une occlu-
sion au ballonnet d’une durée de deux heures, suivie d’une reperfusion d’une durée de
14 jours. Le salvianolate a été administré par voie intraveineuse pendant sept jours à faible
dose (5mg/kg/jour), haute dose (10mg/kg/jour) ou de fortes doses associées à l’injection
intracoronaire en bolus d’une dose de 20mg juste avant le début de la reperfusion. Il n’a été
administré que du sérum salé dans le groupe d’animaux témoins.
Résultats.— Après une reperfusion d’une durée de 14 jours, les porcs traités par de fortes doses
de salvianolate ont eu une amélioration de la perfusion myocardique évaluée par échographie
de contraste myocardique et par microsphère colorée. L’effet bénéﬁque a été amélioré par
l’augmentation de la densité capillaire et la diminution de la taille de l’infarctus. Tous ces
effets observés ont été associés à une amélioration de la fonction ventriculaire gauche, détec-
tée par échographie. De plus, il a été également démontré que l’administration de salvianolate
était associée à une augmentation de l’activité superoxyde dismutase, de l’activité thiore-
doxine et de la concentration de glutathion ainsi qu’une réduction de la concentration de
malondialdehyde, dont la conséquence a été une réduction signiﬁcative de cellules spéciﬁques
portant l’activité deoxynucléotide transférase, médiée par l’UTP et une augmentation du ratio
de l’expression du rapport Bcl-2 sur Bax.
Conclusion.— L’administration intraveineuse de salvianolate à la dose de 10mg/kg/jour pen-
dant sept jours s’accompagne d’effets bénéﬁques sur le ﬂux dans la microcirculation coronaire,
associée à une diminution du stress oxydatif et de l’apoptose.
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bbreviations
AD left anterior descending coronary artery
V left ventricular
BF myocardial blood ﬂow
CE myocardial contrast echocardiography
WF von Willebrand factor
UNEL terminal deoxynucleotide transferase-mediated
dUTP nick end labelling
ackground
eperfusion therapy is the most important therapeutic
trategy for improving the prognosis of patients with
cute myocardial infarction. However, although Throm-
olysis in Myocardial Infarction (TIMI) grade 3 coronary
ow is restored, MCE studies showed that about 20—35%
f patients had severely reduced tissue-level perfusion
c
r
cs droits réservés.
1]. This inadequate tissue perfusion was closely associ-
ted with progressive LV remodelling, leading to severe
ongestive heart failure, and hence, high mortality [2].
adix salviae miltiorrhizae, known as ‘Danshen’, is an
erb that is widely used in the treatment of cardiovascu-
ar diseases in China. The aqueous extract from Danshen
as shown beneﬁcial effects in terms of limiting the size
f an infarct caused by myocardial ischaemia/reperfusion
njury [3,4]. However, it is not clear whether the aqueous
xtract from Danshen can improve myocardial microvascu-
ar reﬂow in the setting of ischaemia/reperfusion injury.
alvianolate, as a highly puriﬁed aqueous extract from
anshen, contains mainly magnesium lithospermate B
≥ 85%), rosmarinic acid (≥ 10.1%) and lithospermic acid
≥ 1.9%) [5]. In the present study, we aimed to determine
hether salvianolate could protect microvascular reﬂowhest porcine model that can minimize the inﬂammatory
esponses induced by open-chest surgery, thus mimicking the
linical situation.
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Methods
Animal procedures
The protocol was approved by the Animal Care and Use Com-
mittee at Shanghai Jiaotong University and conformed to the
Chinese Medical Association guidelines for the use of animals
in research.
On day 1, minipigs (23—30 kg) were sedated with
ketamine (15mg/kg intramuscularly) and anaesthetized
with an intravenous infusion of sodium pentobarbital
(10mg/kg initially, then 1mg/kg as needed), then intubated
and mechanically ventilated. Through a right femoral arte-
rial sheath, a 6-F guiding catheter (Amplatz Left 1) was
placed into the ostium of the left main coronary artery.
The LAD was occluded for 2 h using an intracoronary bal-
loon catheter (15× 2.5mm balloon) at the site distal to
the second diagonal branch. After reperfusion for 2 h, intra-
venous anaesthesia was stopped. Sedation with midazolam
(1mg/kg intramuscularly, as needed) was continued for 24 h,
during which the right femoral artery and vein remained
cannulated for MCE and microsphere injection at 24 h of
reperfusion. Blood pressure and heart rate were continu-
ously monitored. During coronary intervention, pigs were
heparinized (5000U bolus followed by 100U/kg/hour) and
then oral aspirin (300mg) was given daily until euthaniza-
tion.
On day 8 and day 15 (7 and 14 days after reperfusion,
respectively), under sedation with midazolam, the carotid
artery was cannulated for microsphere injection, while the
carotid vein was used for MCE contrast injection.
After 14 days of reperfusion, the LAD was reoccluded and
2% Evans Blue dye was injected into the LAD via a carotid
venous sheath, to identify the risk area. The animals were
then euthanized and the heart was rapidly removed and cut
into ﬁve short-axis slices, perpendicular to the ventricular
septum from the base to the apex of the heart (6—8mm
thick; labelled as S1 to S5, respectively). All ﬁve slices were
weighed and recorded.
Study groups
After LAD occlusion, pigs were randomized into the following
groups: Group I (saline control), normal saline without sal-
vianolate; Group II, 5mg/kg salvianolate diluted with 100mL
saline and given intravenously at a rate of 100mL/hour,
starting 30min before reperfusion; the same dose was
repeated once a day for 7 days; Group III, as for Group II
but using 10mg/kg salvianolate; Group IV, in addition to the
same intravenous dose as Group III, 20mg salvianolate in
2mL saline given through an over-the-wire balloon catheter
just after reperfusion.
Drug under investigation
Salvianolate is derived from the dried root of cultivated
Radix salviae miltiorrhizae and manufactured by Green-
valley Pharmacia (Shanghai, China), using the technique
described previously [6]. Themanufacture and clinical appli-
cation of salvianolate was granted by the State Food and
Drug Administration of China in 2005. The major active
component, magnesium lithospermate B (content > 85%),
M
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s detected for quality control during production. The
ther components of salvianolate consist of different phe-
ol salts, including magnesium lithospermate, dipotassium
ithospermate, sodium rosmarinate, potassium Danshensu,
ipotassium isolithospermate B and magnesium salvianolate
.
Salvianolate is recommended for use at a dose of
00mg/day (3.3mg/kg/day for an adult weighing 60 kg) in
he treatment of chronic stable ischaemic heart disease
7]. The equivalent dose for a minipig is approximately
mg/kg according to the exchange coefﬁcient determined
y surface area. In the present study, we selected an equiv-
lent standard dosage (5mg/kg/day) and a higher dosage
10mg/kg/day) for investigation.
yocardial contrast echocardiography
xamination
n order to detect MBF, real-time MCE was performed with
Sequoia 512 machine (Acuson, Mountain View, CA, USA)
t different time points, including baseline, 2 h after LAD
cclusion, and 2 h, 24 h, 7 days and 14 days after reper-
usion, using the methodology described previously [8].
rieﬂy, after gain settings were optimized, real-time per-
usion images were acquired from the short-axis papillary
uscle view (mechanical index of 0.17), while SonoVue
Bracco Diagnostics, Inc., Geneva, Switzerland) was infused
t a rate of 1mL/minute via a femoral or carotid venous
heath. After high-energy ﬂash frames (mechanical index of
.9) lasting for 10 cardiac cycles were manually triggered to
estroy the microbubbles within the myocardium, continu-
us reﬁlling sequences of 15 cardiac cycles were obtained
nd recorded on magnetic optical disks.
The risk area was identiﬁed as the region of opaciﬁ-
ation defect during LAD occlusion. The perfusion defect
rea was manually traced for the ﬁnal three end-diastolic
mages of the 15-cycle reﬁlling sequence. The risk area was
xpressed as percentage of left ventricle and the reper-
usion defect area was expressed as percentage of risk
rea.
For quantitative analysis, the sample volume was
laced in the risk area (region of interest) avoiding both
he epicardium and the endocardium. Using Cardio U/S
uantiﬁcation software (Version 1.4; Siemens Healthcare,
rlangen, Germany), quantitative perfusion data were
btained by ﬁtting intensity data to an exponential func-
ion: y = A (1−e−t) + C, where y is the signal intensity at any
iven time; A is the plateau signal intensity that reﬂects the
icrovascular cross-sectional area;  is the rate of signal
ntensity rise that reﬂects myocardial microbubble velocity;
is the time after the high-energy ﬂash frames; and C is the
ntercept at the origin reﬂecting the background intensity
evel. The product (A×) correlates with MBF. Because the
alue of A can be affected by various factors, including gain
nd attenuation, it was normalized to the A value derived
rom the adjacent LV cavity [9].
easurement of myocardial blood ﬂowBF was also quantiﬁed using 15m coloured microspheres
Dye-Trak, Triton Technology, Inc., South Easton, MA, USA)
s described previously [10]. Via the femoral or carotid
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rtery sheath, a pigtail catheter was introduced into LV
avity. After being thoroughly vibrated for optimal mix-
ng, an adequate amount of microspheres [11] was injected
nto the LV cavity for 10 s. A 10mL bolus of warm saline
as immediately injected to wash out the catheter. A ref-
rence arterial blood sample was continuously aspirated
rom 10 s before microsphere injection until 60 s after the
njection, at a rate of 5.8mL/minute. The microsphere
njection was repeated at different time points with dif-
erent colours. After the animal was euthanized after 14
ays reperfusion, the anterior wall on the S3 heart tis-
ue slice was used for quantiﬁcation analysis. Microspheres
ere recovered by a sedimentation process. The micro-
phere dye was then extracted and MBF (mL/minute/g) was
alculated.
valuation of the effects of myocardial
ontrast echocardiography and myocardial
lood ﬂow examination on haemodynamics
o ensure that MCE and microsphere examination had no
ide effects on microcirculation, a pilot study was done
n four normal minipigs without any intervention. MCE and
icrosphere injection was done at baseline, and 2 and
h after anaesthesia on days 1, 2, 8 and 15; time course
hanges in microcirculation and cardiac function were quan-
iﬁed.
yocardial function measurement by
ransthoracic echocardiography
hile the animal was sedated for MCE examination at each
ime point, as described above, transthoracic echocardio-
raphy was performed, using a Sequoia 512 machine with
1.75—3.5MHz transducer. LV dimensions and wall thick-
ess were measured from the parasternal short-axis view
t papillary muscle level. Wall thickening and fractional
rea change were calculated and expressed as percentages
12]. LV volume was measured from the apical four-chamber
iew and LV ejection fraction was determined by Simpson’s
ethod.
istological assessment
or infarct size quantiﬁcation, only three slices (S1, S3 and
5) were incubated in 1% triphenyltetrazolium chloride at
7 ◦C for 15minutes. The infarct size (stained in the pale
rea) and risk area (delineated with Evans Blue dye) were
easured by planimetry (ImageJ 1.36, National Institutes
f Health, Bethesda, MD, USA) at both the apical and basal
ides of the three slices. The infarct areas or risk areas for
lices S1, S3 and S5 were the average of the apical and basal
alues of each slice; the values for slice S2 were the average
f the basal side of S3 and the apical side of S1; and the
alues for slice S4 were the average of the basal side of S5
nd the apical side of S3. Summation of the infarct weights
f all slices was obtained and the infarct size was expressed
s a percentage of the total weight of the left ventricle and
s the total weight of the risk area.
The heart tissue slices S2 and S4 were used for immuno-
istochemistry, protein expression and oxidative stress
a
a
o
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easurement. For the histochemistry examination, the tis-
ue was ﬁxed with 4% paraformaldehyde, parafﬁn embedded
nd then sliced at a thickness of 5m. Endothelial cells were
tained using rabbit antihuman vWF antibody (Dako Denmark
/S, Glostrup, Denmark). Capillary density was calculated
n 20 random high-power ﬁelds (400×) and expressed as the
umber per mm2.
erminal deoxynucleotide
ransferase-mediated dUTP nick end labelling
nd endothelial cell staining
UNEL staining was performed using a commercially avail-
ble kit (Nanjing KeyGen Biotech. Co. Ltd., Nanjing,
hina). The cell nuclei were labelled with 4’6-diamidino-
-phenylindole (DAPI), while endothelial cells were labelled
ith antibody against vWF. For each animal, at least 10 ran-
omly selected high-magniﬁcation ﬁelds (400×) from ﬁve
ifferent sections were analysed. The apoptotic index was
alculated as the ratio of TUNEL-positive cells to total cells,
hile the endothelial cell apoptotic index was calculated
s the ratio of TUNEL-positive endothelial cells to total
ndothelial cells.
ssessment of tissue concentrations of
uperoxide dismutase, glutathione,
alondialdehyde and nitric oxide
he tissue levels of superoxide dismutase enzyme activity
nd tissue concentrations of glutathione, malondialdehyde
nd nitric oxide were all determined spectrophotometri-
ally using appropriate kits purchased from the Jiancheng
ioengineering Institute (Nanjing, China), according to
he manufacturer’s instructions. The protein concentra-
ion of heart tissue homogenates was determined with
he bicinchoninic acid (BCA) assay (BioTime Inc., Haimen,
hina).
hioredoxin activity assessment
sing the same method as described previously [13,14],
he activity of thioredoxin was determined for heart tis-
ue from the infarct area using an insulin reduction assay,
here insulin is reduced by thioredoxin with NADPH in the
resence of excess thioredoxin reductase. Brieﬂy, after tis-
ue homogenization, 40g protein in a volume of 68L
lus 2L DTT activation buffer (composed of 50mM HEPES
pH 7.6], 1mM EDTA, 1mg/mL BSA and 2mM DTT) were
ncubated at 37 ◦C for 15min to reduce thioredoxin, then
0L of the reaction mixture (containing 250mM HEPES [pH
.6], 10mM EDTA, 2.4mM NADPH and 6.4mg/mL insulin)
ere added. The reaction began with the addition of 10L
f rat thioredoxin reductase (90.899 A412U/mL; Sigma-
ldrich Inc., St. Louis, MO, USA) followed by incubation
or 20min at 37 ◦C. The reaction was stopped by the
ddition of 0.5mL of 6M guanidine-HCl and 1mM DTNB
3-carboxy-4-nitrophenyl disulﬁde). For each sample, the
bsorbance at 412 nm was adjusted by subtracting the
bsorbance reading without thioredoxin reductase. One unit
f activity was calculated using the following formula:
412 × 0.62/(13.6× 2).
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Table 1 Haemodynamics, microvascular blood ﬂow and left ventricular systolic function in the pilot study (n = 4).
Baseline 2 h* 4 h* 24 h* 7 days† 14 days†
Heart rate
(beats/minute)
116 ± 6 117 ± 9 115 ± 9 114 ± 4 112 ± 7 118 ± 4
Systolic blood
pressure
(mmHg)
151 ± 2 151 ± 5 151 ± 3 152 ± 2 153 ± 5 149 ± 3
Diastolic blood
pressure
(mmHg)
113 ± 3 113 ± 1 112 ± 2 112 ± 2 111 ± 3 111 ± 4
MCE in anterior wall
A 0.57 ± 0.05 0.58 ± 0.04 0.60 ± 0.06 0.58 ± 0.02 0.58 ± 0.02 0.58 ± 0.04
 (sec−1) 0.47 ± 0.05 0.44 ± 0.12 0.43 ± 0.04 0.40 ± 0.05 0.49 ± 0.06 0.45 ± 0.04
A× (sec−1) 0.268 ± 0.016 0.260 ± 0.082 0.259 ± 0.029 0.237 ± 0.035 0.288 ± 0.044 0.263 ± 0.029
MBF by
microspheres
(mL/g/minute)
1.74 ± 0.23 1.94 ± 0.42 1.86 ± 0.63 1.90 ± 0.57 1.53 ± 0.43 1.75 ± 0.70
LV systolic function
Anterior wall
thickening (%)
53.36 ± 6.27 56.22 ± 7.25 54.01 ± 5.98 55.36 ± 5.04 55.54 ± 5.98 53.56 ± 7.27
FAC (%) 60.95 ± 1.98 60.06 ± 2.63 60.30 ± 2.08 61.20 ± 1.18 60.90 ± 1.62 59.86 ± 2.05
LV ejection
fraction (%)
64.37 ± 6.86 64.18 ± 2.45 64.03 ± 1.16 65.21 ± 4.43 64.41 ± 1.88 63.67 ± 1.38
A: plateau signal intensity reﬂecting microvascular cross-sectional area; : rate of signal intensity rise reﬂecting myocardial microbubble
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Mvelocity; FAC: fractional area change; LV: left ventricular; MBF: m
* Hours after anaesthesia; † Days after the ﬁrst examination.
Western blotting
Tissue homogenates was separated by 12% SDS-PAGE and
then transferred to a polyvinylidene-diﬂuoride membrane
(Millipore, Billerica, MA, USA). After blocking with 5%
skimmed milk, membranes were incubated with a ﬁrst anti-
body targeting Bcl-2 and Bax (Santa Cruz Biotechnology,
Inc., Santa Cruz, CA, USA), followed by the corresponding
HRP-conjugated second antibody. An enhanced chemilumi-
nescence reagent western blotting detection kit (Pierce
Biotechnology, Inc., Rockford, IL, USA) was ﬁnally used to
measure immunoreaction with a light-sensitive ﬁlm (Kodak,
Rochester, NY, USA). The band for each protein was then
quantiﬁed by densitometry with ImageJ software.
Statistical analysis
All data are presented as means± standard deviations.
Intergroup differences were determined by one-way anal-
ysis of variance and when statistical signiﬁcance was found
in a group, pairwise comparisons were made using the
Student-Newman-Keuls post-hoc test. A value of P < 0.05 was
considered statistically signiﬁcant.
Results
Time course changes in haemodynamics: pilot
study
In the pilot study, during repeated MCE examination and
microsphere injection, no signiﬁcant changes were detected
c
T
wascular blood ﬂow; MCE: myocardial contrast echocardiography;
n heart rate, blood pressure and LV systolic function, or in
, , (A×) and MBF (Table 1).
aemodynamics, cardiac function and infarct
ize assessment
ive pigs died of ventricular ﬁbrillation after occlusion. Dur-
ng the initial 12 h of reperfusion, one pig died in Group
, one died in Group III and two died in Group IV. The
ata from these animals were excluded. The remaining 33
igs (9 from Group I; 8 from Group II; 8 from Group III; 8
rom Group IV) were evaluated. Heart rate was signiﬁcantly
ncreased (P < 0.001) and blood pressure was signiﬁcantly
ower (P < 0.001) after LAD occlusion (Table 2). However,
here was no signiﬁcant difference between the four groups
n terms of heart rate and blood pressure.
LAD occlusion caused a signiﬁcant decrease in regional
nterior wall thickening, as well as LV ejection fraction
nd fractional area change (P < 0.001, respectively). At 14
ays of reperfusion, these variables were all signiﬁcantly
mproved with high-dose treatment (Groups III and IV) com-
ared with Group I (P < 0.001, respectively; Table 3).
High-dose salvianolate resulted in a signiﬁcant decrease
n infarct size in Group III (p = 0.025) and Group IV (p = 0.032)
ompared with Group I, although there was no signiﬁcant
ifference between Groups III and IV (Table 4).
icrovascular reﬂow by real-time myocardial
ontrast echocardiography
he risk area measured by MCE at 2 h of LAD occlusion
as similar in all groups (Table 4). High-dose salvianolate
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Table 2 Haemodynamic changes during myocardial ischaemia and reperfusion.
Baseline Occlusion Time after reperfusion
2 h 24 h 7 days 14 days
Heart rate (beats/minute)
Group I 116 ± 8 122 ± 6* 102 ± 5*† 115 ± 6†‡ 114 ± 5†‡ 116 ± 5‡
Group II 117 ± 5 126 ± 8* 102 ± 7*† 112 ± 5†‡ 118 ± 9‡ 117 ± 7‡
Group III 116 ± 8 127 ± 6* 102 ± 5*† 113 ± 6†‡ 116 ± 5†‡ 117 ± 7†‡
Group IV 118 ± 6 123 ± 9* 101 ± 9*† 112 ± 5†‡ 117 ± 7‡ 115 ± 7†‡
Systolic blood pressure (mmHg)
Group I 147 ± 6 135 ± 8* 130 ± 8* 142 ± 9‡ 145 ± 7†‡ 144 ± 8†‡
Group II 147 ± 9 131 ± 9* 129 ± 8* 143 ± 5†‡ 142 ± 8†‡ 142 ± 9†‡
Group III 146 ± 6 135 ± 9* 133 ± 9* 139 ± 5 147 ± 9†‡ 143 ± 8†‡
Group IV 147 ± 9 135 ± 8* 132 ± 8* 139 ± 6 145 ± 8†‡ 146 ± 8†‡
Diastolic blood pressure (mmHg)
Group I 113 ± 5 104 ± 5* 101 ± 4* 111 ± 6†‡ 115 ± 6†‡ 114 ± 6†‡
Group II 114 ± 6 99 ± 10* 99 ± 7* 112 ± 8†‡ 111 ± 8†‡ 110 ± 7†‡
Group III 116 ± 6 101 ± 7* 98 ± 8* 112 ± 6†‡ 112 ± 9†‡ 111 ± 7†‡
Group IV 115 ± 7 103 ± 6* 98 ± 5* 112 ± 6†‡ 113 ± 9†‡ 110 ± 8†‡
* P < 0.05 vs baseline within the same group, † P < 0.05 vs occlusion within the same group, ‡ P < 0.05 vs at 2 h of reperfusion within the
same group.
a
c
P
i
r
udministration (Groups III and IV) resulted in a signiﬁ-
ant decrease in the defect area after reperfusion (Fig. 1;
< 0.001, respectively; Table 4).
Quantitative MCE showed a reduction in A,  and (A×)
n LAD territories after occlusion (P < 0.001). The variables
a
i
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Table 3 Left ventricular systolic function by transthoracic ec
Baseline Occlusion Time after re
2 h
Anterior wall thickening (%)
Group I 52.18 ± 5.02 2.13 ± 2.31* 4.29 ± 1.58*
Group II 51.76 ± 6.21 2.93 ± 3.22* 5.87 ± 2.65*
Group III 56.55 ± 8.37 2.45 ± 1.42* 7.89 ± 2.71*
Group IV 54.83 ± 8.82 2.50 ± 1.71* 8.69 ± 2.17*
FAC (%)
Group I 63.29 ± 3.85 37.87 ± 3.88* 44.51 ± 8.25*
Group II 65.27 ± 6.02 39.01 ± 3.59* 46.30 ± 2.75*
Group III 65.89 ± 6.48 38.02 ± 1.88* 50.28 ± 3.54*
Group IV 66.94 ± 4.81 37.79 ± 5.44* 51.45 ± 3.82*
LV ejection fraction (%)
Group I 64.69 ± 2.05 50.78 ± 2.98* 52.02 ± 2.79*
Group II 65.99 ± 1.60 49.88 ± 2.95* 54.09 ± 3.35*
Group III 64.80 ± 3.61 48.84 ± 3.09* 56.89 ± 4.53*
Group IV 66.45 ± 1.84 48.88 ± 2.65* 57.71 ± 2.00*
FAC: fractional area change; LV: left ventricular; * P < 0.05 vs baseline
group; ‡ P < 0.05 vs at 2 h of reperfusion within the same group; § P < 0
at 7 days of reperfusion within the same group; # P < 0.05 vs Group I atecovered at the onset of reperfusion but deteriorated grad-
ally over the following 14 days. Compared with Group I,
fter reperfusion for 14 days, the variables were signiﬁcantly
mproved in Groups III and IV (P <0.001; Table 5). No signif-
cant difference was detected between Groups III and IV.
hocardiography.
perfusion
24 h 7 days 14 days
5.77 ± 0.97*† 6.40 ± 1.65*† 9.04 ± 2.85*†‡§||
7.88 ± 2.06*† 8.55 ± 2.18*†# 10.29 ± 0.78*†‡
9.85 ± 1.87*†# 11.29 ± 1.70*†# 13.90 ± 8.52*†#
† 11.08 ± 2.31*†# 11.62 ± 1.81*†# 16.17 ± 2.92*†‡§#
† 44.57 ± 1.90*† 47.06 ± 1.85*† 50.38 ± 2.87*†‡§
† 48.55 ± 4.67*† 50.70 ± 5.12*†‡ 51.86 ± 2.57*†‡
† 52.32 ± 4.51*†# 57.43 ± 4.94*†‡§# 58.43 ± 4.17*†‡§#
† 54.87 ± 3.10*†# 55.28 ± 1.50*†‡# 57.77 ± 1.18*†‡#
49.14 ± 3.77* 48.93 ± 3.50*‡ 53.41 ± 2.96*§||
† 52.27 ± 3.45* 51.88 ± 2.61* 56.06 ± 1.72*†§||
† 58.53 ± 2.29*†# 59.18 ± 6.38*†# 60.64 ± 6.14†#
† 57.08 ± 4.00*†# 58.89 ± 4.94*†# 60.03 ± 5.39*†#
within the same group; † P < 0.05 vs occlusion within the same
.05 vs at 24 h of reperfusion within the same group; || P < 0.05 vs
the same time point.
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Table 4 Opaciﬁcation defect area by myocardial contrast echocardiography and infarct size by triphenyltetrazolium
chloride.
Opaciﬁcation defect area by MCE Infarct size by TTC
Risk area (% of
total LV area)
% of risk area
after reperfusion
(% of the total LV)
2 h 24 h 7 days 14 days
Group I 23.19 ± 4.76 75.90 ± 9.99 83.51 ± 10.19 88.40 ± 14.32* 86.92 ± 13.63 26.16 ± 9.53
Group II 22.19 ± 4.28 67.56 ± 7.17 74.89 ± 17.99 77.77 ± 18.78 76.32 ± 17.69 21.01 ± 6.71
Group III 24.14 ± 11.59 51.25 ± 14.45† 55.16 ± 13.60† 56.69 ± 7.51† 56.27 ± 5.05† 16.95 ± 5.70†
Group IV 21.33 ± 5.30 47.51 ± 6.41† 53.13 ± 7.72† 52.26 ± 12.60† 53.65 ± 15.34† 17.26 ± 7.87†
LV: left ventricular; MCE: myocardial contrast echocardiography; TTC: triphenyltetrazolium chloride; * P < 0.05 vs at 2 h of reperfusion
within the same group; † P < 0.05 vs Group I at the same time point.
w
dMyocardial blood ﬂow examinationMBF measured by microspheres revealed the severe
decrease in blood ﬂow in the LAD regions after occlusion
(P < 0.001). At the onset of reperfusion, MBF recovered sig-
niﬁcantly but decreased gradually thereafter. Compared
s
I
a
Figure 1. Representative myocardial contrast echocardiography imag
reperfusion in different groups. Panels A, B, C and D show images from G
bold white arrows. The perfusion defect area is shown between slim
signiﬁcantly smaller in Panels C and D compared with Panel A.ith Group I, MBF was signiﬁcantly higher in the high-
ose groups (Groups III and IV; P < 0.001; Table 5). No
igniﬁcant difference was found between Groups III and
V.
The variable (A×) derived by MCE correlated with MBF
ssessed by microspheres (r = 0.785; P < 0.001).
es of the left ventricle at papillary muscle level taken at 2 h of
roups I, II, III and IV, respectively. The risk area is shown between
white arrows. The ratio of perfusion defect area to risk area is
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Table 5 Myocardial blood ﬂow assessed by quantitative myocardial contrast echocardiography and microspheres in left anterior descending coronary artery territory.
Baseline Occlusion Time after reperfusion
2 h 24 h 7 days 14 days
A
Group I 0.57 ± 0.04 0.03 ± 0.01* 0.42 ± 0.09*† 0.37 ± 0.07*† 0.33 ± 0.06*†‡ 0.34 ± 0.07*†‡
Group II 0.56 ± 0.04 0.03 ± 0.01* 0.46 ± 0.07*† 0.41 ± 0.07*† 0.38 ± 0.05*†‡ 0.39 ± 0.04*†‡
Group III 0.59 ± 0.04 0.03 ± 0.00* 0.54 ± 0.08†|| 0.51 ± 0.09*†|| 0.52 ± 0.06*†|| 0.52 ± 0.09*†||
Group IV 0.58 ± 0.04 0.03 ± 0.01* 0.57 ± 0.06†|| 0.52 ± 0.07†|| 0.53 ± 0.07†|| 0.51 ± 0.09†||
ˇ (sec−1)
Group I 0.48 ± 0.11 0.04 ± 0.02* 0.21 ± 0.06*† 0.21 ± 0.05*† 0.12 ± 0.05*†‡§ 0.11 ± 0.05*†‡§
Group II 0.50 ± 0.12 0.05 ± 0.02* 0.20 ± 0.05*† 0.19 ± 0.07*† 0.16 ± 0.07*† 0.15 ± 0.06*†
Group III 0.46 ± 0.08 0.05 ± 0.02* 0.53 ± 0.19†|| 0.46 ± 0.09†|| 0.34 ± 0.10*†‡§|| 0.33 ± 0.09*†‡§||
Group IV 0.45 ± 0.09 0.05 ± 0.03* 0.47 ± 0.14†|| 0.42 ± 0.07†|| 0.32 ± 0.11*†‡§|| 0.32 ± 0.09*†‡§||
(A×ˇ) (sec−1)
Group I 0.276 ± 0.070 0.001 ± 0.010* 0.092 ± 0.037*† 0.076 ± 0.027*† 0.038 ± 0.019*†‡§ 0.037 ± 0.019*†‡§
Group II 0.280 ± 0.070 0.001 ± 0.005* 0.094 ± 0.030*† 0.079 ± 0.029*† 0.064 ± 0.031*† 0.058 ± 0.027*†
Group III 0.271 ± 0.034 0.001 ± 0.001* 0.282 ± 0.076†|| 0.228 ± 0.047†‡|| 0.177 ± 0.053*†‡§|| 0.171 ± 0.049*†‡§||
Group IV 0.260 ± 0.051 0.011 ± 0.006* 0.268 ± 0.087†|| 0.228 ± 0.045†|| 0.165 ± 0.054*†‡§|| 0.158 ± 0.037*†‡§||
MBF by microspheres (mL/g/minute)
Group I 1.70 ± 0.08 0.73 ± 0.10* 0.96 ± 0.25*† 1.03 ± 0.12*† 0.90 ± 0.08*† 0.88 ± 0.24*§
Group II 1.71 ± 0.20 0.72 ± 0.08* 1.05 ± 0.23*† 1.05 ± 0.16*† 1.03 ± 0.13*† 0.96 ± 0.27*†
Group III 1.67 ± 0.14 0.73 ± 0.07* 1.39 ± 0.25*†|| 1.27 ± 0.09*†|| 1.24 ± 0.15*†|| 1.25 ± 0.16*†||
Group IV 1.65 ± 0.14 0.74 ± 0.19* 1.46 ± 0.16*†|| 1.35 ± 0.11*†|| 1.26 ± 0.15*†‡|| 1.36 ± 0.19*†||
A: plateau signal intensity reﬂecting microvascular cross-sectional area; : rate of signal intensity rise reﬂecting myocardial microbubble velocity; MBF: microvascular blood ﬂow; *
P < 0.05 vs baseline within the same group; † P < 0.05 vs occlusion within the same group; ‡ P < 0.05 vs at 2 h of reperfusion within the same group; § P < 0.05 vs at 24 h of reperfusion
within the same group; || P < 0.05 vs Group I at the same time point.
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Figure 2. A: representative immunohistochemical staining with antibody against von Willebrand factor for endothelial cells (stained in
brown); panels a, b, c and d are from Groups I, II, III and IV, respectivel
P < 0.05 vs Group I. Data are expressed as means± standard deviations.
Table 6 Effects of salvianolate on oxidative stress in reperfus
Total superoxide
dismutase activity
(U/mg protein)
Glutathione
(mg/g protein)
Malondi
(nmol/m
Group I 7.52 ± 2.70 21.77 ± 6.93 3.47 ±
Group II 8.84 ± 2.40 24.37 ± 11.53 3.02 ±
Group III 14.80 ± 2.24* 40.94 ± 10.84* 2.13 ±
Group IV 14.23 ± 2.10* 48.11 ± 12.95* 2.41 ±
* P < 0.05 vs Group I.y. B: quantiﬁcation of capillary density is shown for each group. *
ed myocardium on day 14 after reperfusion.
aldehyde
g protein)
Nitric oxide
(mol/g protein)
Thioredoxin activity
(U/mg protein)
0.97 3.78 ± 1.39 0.29 ± 0.07
0.88 3.82 ± 1.53 0.32 ± 0.06
0.72* 4.21 ± 2.44 0.39 ± 0.10*
0.97* 4.02 ± 1.24 0.42 ± 0.04*
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Figure 3. Upper panel: representative terminal deoxynucleotide transferase-mediated dUTP nick end labelling staining from each group;
panels A, B, C and D are from Groups I, II, III and IV, respectively. Apoptotic nuclei are stained green, nuclei stained with 4’6-diamidino-2-
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chenylindole (DAPI) are blue and endothelial cells stained with anti
ata, the apoptosis ratios of total cells and endothelial cells. * P < 0
mmunohistochemical staining for capillary
ensity measurement
he density of capillaries that stained positive for vWF
n the ischaemic area was signiﬁcantly higher in Group II
895± 311/mm2), Group III (855± 92/mm2) and Group IV
588± 99/mm2) compared with Group I (350± 146/mm2;
< 0.001, respectively; Fig. 2) with no signiﬁcant differences
etween the salvianolate groups.
t
d
Tagainst von Willebrand factor are red. Lower panel: quantiﬁcation
s Group I. Data are expressed as means± standard deviations.
ffect of salvianolate on myocardial oxidative
tress
igh-dose salvianolate (Groups III and IV) resulted in a
igher level of superoxide dismutase activity and a higher
oncentration of glutathione in heart tissue, whereas
he concentration of malondialdehyde was signiﬁcantly
ecreased, compared with Group I (P < 0.001, respectively;
able 6). Interestingly, the concentration of nitric oxide in
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Figure 4. Panel A: representative protein band for Bcl-2 (upper
lane) and Bax (lower lane) from different group animals. Panel B:
a
s
d
c
a
t
N
s
f
s
M
v
m
d
f
P
c
s
w
o
t
r
t
i
I
i
i
i
h
m
t
i
[
m
p
i
n
i
s
b
o
s
s
r
k
i
O
d
i
t
T
t
k
s
BBcl-2/Bax protein expression ratio. * P < 0.05 vs Group I. Data are
expressed as means± standard deviations.
the infarcted area was not signiﬁcantly different between
the four groups.
Effect of salvianolate on myocardial
thioredoxin activity
Myocardial thioredoxin activity was signiﬁcantly increased in
Groups III and IV compared with Group I (P < 0.001, respec-
tively).
Effect of salvianolate on apoptosis
TUNEL staining showed that the apoptosis ratios for total
cells and endothelial cells in the infarct area were signiﬁ-
cantly decreased in Groups III and IV, compared with controls
(P < 0.001, respectively, Fig. 3).
Consistently, the ratio of Bcl-2/Bax was signiﬁcantly
higher in Groups III and IV than in Group I (P < 0.001, respec-
tively; Fig. 4).
Discussion
The present study for the ﬁrst time investigated the pro-
tective effect of salvianolate, a highly puriﬁed aqueous
extract from Danshen, on microcirculation after myocardial
ischaemia/reperfusion injury. Impaired microvascular circu-
lation is a pathological process that begins during ischaemia
c
t
w
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nd progresses upon reperfusion, the mechanism of which is
till not fully understood [15]. We deliberately delivered the
rug during the ischaemic period, allowing a stable blood
oncentration be established before reperfusion started,
lthough the protective effects might also involve attenua-
ion of ischaemic injury rather than pure reperfusion injury.
evertheless, in the present study, we clearly showed that
alvianolate given intravenously at a dose of 10mg/kg/day
or 7 days, with the ﬁrst dose delivered before reperfusion,
igniﬁcantly limited reperfusion defect size expansion on
CE, and enhanced MBF recovery, as evidenced by an ele-
ated (A×) value on MCE and MBF measured by coloured
icrospheres. The protection provided by salvianolate, evi-
enced by a decrease in infarct size and enhanced LV systolic
unction, was also present at a high dose of salvianolate.
revious pharmacokinetic studies have veriﬁed that blood
oncentration linearly correlates with the dose of magne-
ium lithospermate B, the major component of salvianolate,
hen given intravenously [16]. We also observed a trend
f dose-dependent effects with most of the variables we
ested, which was not statistically signiﬁcant. However, our
esults suggest that a high dose may be necessary to achieve
he maximal minimizing effect on ischaemia/reperfusion
njury; this has been suggested in previous studies [4,17].
n addition, we also observed that one extra intracoronary
njection of 20mg salvianolate, delivered directly to the
schaemic myocardium, failed to provide further protection,
ndicating that maximal effects might be reached with the
igh dose of intravenous salvianolate alone.
Microsphere injection has been shown to quantify
icrovascular blood ﬂow precisely without affecting sys-
emic haemodynamic variables [10,18]; this was conﬁrmed
n our pilot study, with dose carefully adjusted by weight
11]. Thus, our data suggest that repeated injections of
icrospheres do not signiﬁcantly affect microcirculation.
In our study, triphenyltetrazolium chloride staining was
erformed 14 days after reperfusion. However, when we
njected Evans Blue dye to delineate the risk area, we
oticed that the dye can perfuse into the risk zone, mak-
ng this methodology impractical for quantiﬁcation of infarct
ize at the late phase of reperfusion. This phenomenon could
e due to neovascularization in the risk zone after 14 days
f reperfusion [19]. Fortunately, however, the risk zone can
till be clearly deﬁned by MCE examination. Thus, the infarct
ize was expressed as a percentage of the total left ventricle
ather than the risk area.
Overproduction of oxygen-derived free radicals plays a
ey role in ischaemia/reperfusion injury [20], leading to
ncreased apoptosis activation during reperfusion [21,22].
ur data show that a high dose of salvianolate resulted in a
ecrease in malondialdehyde concentration and an increase
n superoxide dismutase activity, glutathione concentra-
ion and thioredoxin activity in the ischaemic myocardium.
hioredoxin has been recently proven to be crucial for main-
aining activity of antioxidative enzymes [23] and plays a
ey role in the antiapoptotic signalling pathway [24]. In our
tudy, this protection was evidenced by an increase in the
cl-2/Bax protein expression ratio and suppressed apoptotic
ells, especially apoptotic endothelial cells. Our observa-
ions were consistent with previous reports [25—27]. Thus,
e have conﬁrmed that salvianolate improves microvascular
eﬂow via suppression of oxidative stress and apoptosis.
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The recommended dose of 200mg/day has been proven
o be safe by several experimental and clinical studies [7].
n our present study, no signiﬁcant changes in arterial blood
ressure and heart rate were observed during salvianolate
nfusion. Thus, an intravenous dose of 10mg/kg/day (equiv-
lent to a dose of 400mg/day in humans) is safe for pigs.
large-scale clinical study is certainly warranted to further
valuate its beneﬁcial effects and drug-related side effects.
In conclusion, using a closed-chest porcine model of
yocardial ischaemia/reperfusion injury, we demonstrated
hat 7-day treatment with high-dose salvianolate (10mg/kg
er day, intravenously) signiﬁcantly improved microvascu-
ar reﬂow, resulting in smaller infarct size and enhanced
V systolic function. The protective effect of salvianolate
as closely associated with its strong antioxidative and anti-
poptotic effects.
isclosure of interest
he authors declare that they have no conﬂicts of interest
oncerning this article.
cknowledgement
his research project was supported by the Science and
echnology Commission of Shanghai Municipality (Pro-
ramme 064119507 to M. W.), and partly supported by China
atural Science Foundation (81070110, to WEI M).
eferences
[1] Ragosta M, Camarano G, Kaul S, et al. Microvascular
integrity indicates myocellular viability in patients with recent
myocardial infarction. New insights using myocardial contrast
echocardiography. Circulation 1994;89:2562—9.
[2] Ito H, Maruyama A, Iwakura K, et al. Clinical implications of the
‘no reﬂow’ phenomenon. A predictor of complications and left
ventricular remodeling in reperfused anterior wall myocardial
infarction. Circulation 1996;93:223—8.
[3] Jin S, Zhao G, Fan Y. Effect of salvianolic acid B
on endothelin release and TXA2/PGI2 system in myocar-
dial ischemia/reperfusion injury in rats. Chin J Gerontol
2004;24:127—8.
[4] Xu JP, Sun LS, Wu HY, et al. Protective effect of salvianolic
acid B on myocardial ischemia/reperfusion in rats. Chin Pharm
J 2003;38:595—7.
[5] Li X, Yu C, Sun W, et al. Simultaneous determina-
tion of magnesium lithospermate B, rosmarinic acid, and
lithospermic acid in beagle dog serum by liquid chromatogra-
phy/tandem mass spectrometry. Rapid Commun Mass Spectrom
2004;18:2878—82.
[6] Xu YM, J. XL, Li T, et al. Methods for identiﬁcation, puriﬁca-
tion, and manufacturing of the active constituents in Salvia
miltiorrhiza (Dansheng) and the application of this product in
enhancing cardiovascular functions. http://www.patentstorm.
us/patents/6299910/description.html 2001; United States
Patent 6299910.
[7] Yan P, Luo X, Shi H, et al. Effect of depside salt from salvia
miltiorrhiza on angina pectoris and platelet function. Jie Ru
Fang She Xue Za Zhi 2004;12(Suppl. 2):55—9.
[B. Han et al.
[8] Wei K, Jayaweera AR, Firoozan S, et al. Quantiﬁcation of
myocardial blood ﬂow with ultrasound-induced destruction of
microbubbles administered as a constant venous infusion. Cir-
culation 1998;97:473—83.
[9] Pacella JJ, Villanueva FS. Effect of coronary stenosis on
adjacent bed ﬂow reserve: assessment of microvascular
mechanisms using myocardial contrast echocardiography. Cir-
culation 2006;114:1940—7.
10] Kowallik P, Schulz R, Guth BD, et al. Measurement of regional
myocardial blood ﬂow with multiple colored microspheres. Cir-
culation 1991;83:974—82.
11] Hoffmann U, Millea R, Enzweiler C, et al. Acute myocar-
dial infarction: contrast-enhanced multi-detector row CT in a
porcine model. Radiology 2004;231:697—701.
12] Hasegawa H, Takano H, Iwanaga K, et al. Cardioprotective
effects of granulocyte colony-stimulating factor in swine with
chronic myocardial ischemia. J Am Coll Cardiol 2006;47:
842—9.
13] Holmgren A, Bjornstedt M. Thioredoxin and thioredoxin reduc-
tase. Methods Enzymol 1995;252:199—208.
14] Yegorova S, Liu A, Lou MF. Human lens thioredoxin: molecular
cloning and functional characterization. Invest Ophthalmol Vis
Sci 2003;44:3263—71.
15] Rezkalla SH, Kloner RA. No-reﬂow phenomenon. Circulation
2002;105:656—62.
16] Li XC, Yu C, Sun WK, et al. Pharmacokinetics of magnesium
lithospermate B after intravenous administration in beagle
dogs. Acta Pharmacol Sin 2004;25:1402—7.
17] Chen YH, Du GH, Zhang JT. Salvianolic acid B protects brain
against injuries caused by ischemia-reperfusion in rats. Acta
Pharmacol Sin 2000;21:463—6.
18] Theilmeier G, Verhamme P, Dymarkowski S, et al. Hyperc-
holesterolemia in minipigs impairs left ventricular response
to stress: association with decreased coronary ﬂow reserve
and reduced capillary density. Circulation 2002;106:1140—
6.
19] Vandervelde S, van Amerongen MJ, Tio RA, et al. Increased
inﬂammatory response and neovascularization in reperfused
vs. non-reperfused murine myocardial infarction. Cardiovasc
Pathol 2006;15:83—90.
20] Kaul S, Ito H. Microvasculature in acute myocardial ischemia:
part II: evolving concepts in pathophysiology, diagnosis, and
treatment. Circulation 2004;109:310—5.
21] Zhao ZQ, Velez DA, Wang NP, et al. Progressively developed
myocardial apoptotic cell death during late phase of reperfu-
sion. Apoptosis 2001;6:279—90.
22] Zhao ZQ, Vinten-Johansen J. Myocardial apoptosis and ischemic
preconditioning. Cardiovasc Res 2002;55:438—55.
23] World CJ, Yamawaki H, Berk BC. Thioredoxin in the cardiovas-
cular system. J Mol Med 2006;84:997—1003.
24] Liu Y, Min W. Thioredoxin promotes ASK1 ubiquitination
and degradation to inhibit ASK1-mediated apoptosis in a
redox activity-independent manner. Circ Res 2002;90:1259—
66.
25] Kim SH, Choi M, Lee Y, et al. Natural therapeutic mag-
nesium lithospermate B potently protects the endothelium
from hyperglycaemia-induced dysfunction. Cardiovasc Res
2010;87:713—22.
26] Liu X, Chen R, Shang Y, et al. Superoxide radicals scavenging
and xanthine oxidase inhibitory activity of magnesium lithos-
permate B from Salvia miltiorrhiza. J Enzyme Inhib Med Chem
2009;24:663—8.27] Wang MW, Zhang DF, Tang JJ, et al. Effects of salvianolate on
cardiomyocytic apoptosis and heart function in a swine model
of acute myocardial infarction. Zhong Xi Yi Jie He Xue Bao
2009;7:140—4.
